TORONTO, Jan. 13, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) today announced its President and CEO, Anthony Giovinazzo, will present an overview of the Company's Parkinson’s disease (“PD”) program and outlook at the NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 18, 2016 at 12:30 p.m. EST in Room 1.
Following the conclusion of the conference on January 22, 2016, a high-definition video webcast of Cynapsus’ presentation and a copy of the presentation materials will be available on the Company's web site, www.cynapsus.ca, in the Investor’s section, or through the Noble Financial websites: www.noblefcm.com or www.nobleconference.com. You will need a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the Company's website and on the Noble websites for 90 days following the event.
Cynapsus is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with PD. The Company recently completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a “turning ON” medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus has initiated its Phase 3 clinical program for APL-130277, relying on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the Company intends to submit a new drug application (“NDA”) in 2016.
About Noble Financial Capital Markets
Noble Financial Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. Noble has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous “non-deal” corporate road shows and sector-specific conferences. Members: FINRA, SIPC, MSRB. www.noblefcm.com
This announcement contains "forward-looking statements" within the meaning of applicable securities laws, including, without limitation, filing an NDA in 2016. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. These forward-looking statements are based on the Company’s current expectations and beliefs and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ from those anticipated in such forward-looking statements as a result of risks and uncertainties, and include, but are not limited to, those factors identified under the caption “Risk Factors” in the Company’s Form 10-Q filed with the United States Securities and Exchange Commission (the “SEC”) on November 12, 2015 and its other filings and reports in the United States with the SEC available on the SEC’s web site at www.sec.gov, and in Canada with the various Canadian securities regulators, which are available online at www.sedar.com. Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of this press release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes or otherwise, except as required by law.
Neither the NASDAQ nor the TSX has approved or disapproved of the contents of this press release.
Contact Information Cynapsus Kristen Galfetti Vice President Investor Relations (416) 703-2449 x246 email@example.com Media Contact: Russo Partners LLC Matt Middleman (212) 845-4272 firstname.lastname@example.org
Source:Cynapsus Therapeutics Inc.